<description>&lt;p&gt;Yet more GLP1 news this week. &lt;/p&gt; &lt;p class="p1"&gt;People regain on average 60% of their lost weight within a year of stopping GLP-1 drugs — and the regained weight may be disproportionately fat rather than muscle. &lt;/p&gt; &lt;p class="p1"&gt;So are a tool that biohackers have known about for years - CGMs - the answer? &lt;/p&gt; &lt;p class="p1"&gt;Sharam Fouladgar-Mercer is the co-founder of Signos, the first ever FDA-cleared glucose system for weight management.&lt;/p&gt; &lt;p class="p1"&gt;Follow &lt;a href= "https://www.linkedin.com/in/sharamfm/"&gt;Sharam Fouladgar-Mercer&lt;/a&gt; on LinkedIn.&lt;/p&gt;</description>

Biohacking News by Zestology

Tony Wrighton

Ozempic Vs. Glucose Monitors (feat. Sharam Fouladgar-Mercer) #685

MAR 30, 202632 MIN
Biohacking News by Zestology

Ozempic Vs. Glucose Monitors (feat. Sharam Fouladgar-Mercer) #685

MAR 30, 202632 MIN

Description

Yet more GLP1 news this week. People regain on average 60% of their lost weight within a year of stopping GLP-1 drugs — and the regained weight may be disproportionately fat rather than muscle. So are a tool that biohackers have known about for years - CGMs - the answer? Sharam Fouladgar-Mercer is the co-founder of Signos, the first ever FDA-cleared glucose system for weight management. Follow Sharam Fouladgar-Mercer on LinkedIn.